Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance for Relapsed/Refractory Follicular Lymphoma
NCT02390869Phase 3Active, not recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- May 2014
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenalidomide in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-Free Survival at 2 years. Started May 2014; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02390869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390869.